CBL-0137

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameCBL-0137
Drug Alias NameCuraxin-CBL0137CBLC-137CX-137CBL-0137
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor protein p53 stimulantsStructure specific recognition protein 1 inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complexStructure specific recognition protein 1Tumor protein p53
Therapy Area/IndicationsSkin MelanomaSolid tumoursDiffuse midline glioma +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCleveland Biolabs Inc
China Registration ClassN/A

Develop Information

Active CompaniesIncuron LLC
Inactive CompaniesRoswell Park Cancer Institute
Active IndicationsSolid tumoursDiffuse midline gliomaCentral Nervous System Neoplasms +[5] 
Inactive IndicationsSkin MelanomaHematologic NeoplasmsGlioblastoma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A